Complement resistance of tumor cells:: Basal and induced mechanisms

被引:177
作者
Jurianz, K
Ziegler, S
Garcia-Schüler, H
Kraus, S
Bohana-Kashtan, O
Fishelson, Z
Kirschfink, M
机构
[1] Univ Heidelberg, Inst Immunol, D-69120 Heidelberg, Germany
[2] Tel Aviv Univ, Sackler Sch Med, Dept Cell Biol & Histol, IL-69978 Tel Aviv, Israel
关键词
complement; regulation; tumor; resistance mechanisms;
D O I
10.1016/S0161-5890(99)00115-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Clinical and experimental studies have suggested that complement may play a role in tumor cytotoxicity. However, the efficiency of complement-mediated tumor cell lysis is hampered by various protective mechanisms, which may be divided into two categories: basal and induced mechanisms. The basal mechanisms are spontaneously expressed in cells without a need for prior activation, whereas the induced mechanisms develop in cells subjected to stimulation with cytokines, hormones, drugs or with sublytic doses of complement and other pore-formers. Membrane-associated complement regulatory proteins, such as CD55 (DAF, Decay-Accelerating Factor), CD46 (MCP, Membrane Cofactor Protein), CD35 (CR1, Complement Receptor type 1) and CD59, which serve as an important mechanism of self protection and render autologous cells insensitive to the action of complement, appear to be over-expressed on certain tumors. Furthermore, tumor cells secrete several soluble complement inhibitors. Tumor cells may also express proteases that degrade complement proteins, such as C3, or ecto-protein kinases which can phosphorylate complement components, such as C9. Besides this basal resistance, nucleated cells resist, to some extent, complement damage by removing the membrane attack complexes (MAC) from their surface. Several biochemical pathways, including protein phosphorylation, activation of G-proteins and turnover of phosphoinositides have been implicated in resistance to complement. Calcium ion influx and activation of protein kinase C (PKC) and of mitogen-activated protein kinase (MAPK) have also been demonstrated to be associated with the complement-induced enhanced resistance to lysis. The complete elucidation of the molecular mechanisms involved in basal and induced tumor cell resistance will enable the development of strategies for interfering with these evasion mechanisms and the use of the cytotoxic complement system against tumor cells. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:929 / 939
页数:11
相关论文
共 111 条
[1]   CATHEPSIN-B, CATHEPSIN-L, AND CATHEPSIN-D ACTIVITIES IN COLORECTAL CARCINOMAS - RELATIONSHIP WITH CLINICOPATHOLOGICAL PARAMETERS [J].
ADENIS, A ;
HUET, G ;
ZERIMECH, F ;
HECQUET, B ;
BALDUYCK, M ;
PEYRAT, JP .
CANCER LETTERS, 1995, 96 (02) :267-275
[2]   AUTOANTIBODY-MEDIATED ACQUIRED DEFICIENCY OF C1 INHIBITOR [J].
ALSENZ, J ;
BORK, K ;
LOOS, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (22) :1360-1366
[3]   Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes [J].
Badea, TC ;
Niculescu, FI ;
Soane, L ;
Shin, ML ;
Rus, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (41) :26977-26981
[4]   Differential expression of complement proteins and regulatory decay accelerating factor in relation to differentiation of cultured human colon adenocarcinoma cell lines [J].
BernetCamard, MF ;
Coconnier, MH ;
Hudault, S ;
Servin, AL .
GUT, 1996, 38 (02) :248-253
[5]   THE INFLUENCE OF TUMOR-NECROSIS-FACTOR-ALPHA, INTERLEUKIN-1-BETA AND INTERFERON-GAMMA ON THE EXPRESSION AND FUNCTION OF THE COMPLEMENT REGULATORY PROTEIN CD59 ON THE HUMAN COLONIC ADENOCARCINOMA CELL-LINE HT29 [J].
BJORGE, L ;
JENSEN, TS ;
ULVESTAD, E ;
VEDELER, CA ;
MATRE, R .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1995, 41 (04) :350-356
[6]   Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF,CD55) and membrane cofactor protein (MCP,CD46) on a human colonic adenocarcinoma cell line [J].
Bjorge, L ;
Jensen, TS ;
Matre, R .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (03) :185-192
[7]  
Bjorge L, 1997, INT J CANCER, V70, P14, DOI 10.1002/(SICI)1097-0215(19970106)70:1<14::AID-IJC3>3.0.CO
[8]  
2-9
[9]  
BJORGE L, 1994, EUR J IMMUNOL, V24, P1597
[10]   DOWN-REGULATION OF CD59 (PROTECTIN) EXPRESSION ON HUMAN COLORECTAL ADENOCARCINOMA CELL-LINES BY LEVAMISOLE [J].
BJORGE, L ;
MATRE, R .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1995, 42 (05) :512-516